Prospect Bio
Prospect Bio, a synthetic biology firm, innovates affordable, scalable biosensors for diverse industries, enhancing testing processes and supply chain assurance.
Founded
2013Prospect Bio, a synthetic biology firm, innovates affordable, scalable biosensors for diverse industries, enhancing testing processes and supply chain assurance.
Prospect Bio is a synthetic biology company that specializes in building biosensors (living cells) that can measure chemicals. Biosensors are powerful measurement tools which can perform highly complex testing tasks while being near costless to manufacture, field deployable, and massively scalable. As such, Prospect's work generally focusses on taking broken testing processes - often ones that rely on expensive ($0.5M+), slow, and lab-bound equipment - and replacing them with an affordable, scalable, and on-site biosensor based solutions.
The need for improved testing solutions is being driven on a variety of fronts, including growing regulation, increased QC, and concerns about supply chain assurance. This problem set affects numerous industries, as shown by Prospect's diverse partner list which includes one of the three largest wine companies in the the world, a leading California-based Ag company, a prenatal diagnostics maker, and Ginkgo Bioworks. Prospect Bio has raised $2.8M, and is supported by investors including Illumina, Viking Capital, Stanford-StartX, Digital Sky Technologies, and Rising Tide Fund.
Companies similar to Prospect Bio include Stemloop, Innovative Biosensors, Applied Biosensors and Monod Bio.
Prospect Bio was founded in 2013.
Prospect Bio's headquarters is located in Brisbane, CA, US.
Prospect Bio's most recent funding round was for $2.8M (USD) in November 2016.
As of Nov 15, 2016, Prospect Bio has disclosed funding of $2.8M (USD). Undisclosed round amounts are excluded.
Prospect Bio has 30 employees as of Feb 4, 2024.
Monod Bio
monod.bio
